Evidence map›Paper›PMID 31881700›Full record

ArticleMolecules (Basel, Switzerland)2019

The

Izabela Jęśkowiak, Stanisław Ryng, Marta Świtalska, Joanna Wietrzyk, Iwona Bryndal, Tadeusz Lis, Marcin Mączyński

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Izabela JęśkowiakDepartment of Organic Chemistry, Faculty of Pharmacy, Wrocław Medical University, 211A Borowska Str, 50-556 Wrocław, Poland.ORCID 0000-0002-8829-4482
Stanisław RyngDepartment of Organic Chemistry, Faculty of Pharmacy, Wrocław Medical University, 211A Borowska Str, 50-556 Wrocław, Poland.ORCID 0000-0002-4344-706X
Marta ŚwitalskaInstitute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wrocław, Poland.
Joanna WietrzykInstitute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wrocław, Poland.ORCID 0000-0003-4980-6606
Iwona BryndalDepartment of Drug Technology, Faculty of Pharmacy, Wrocław Medical University, 211A Borowska Str, 50-556 Wrocław, Poland.
Tadeusz LisFaculty of Chemistry, University of Wrocław, 14 Joliot-Curie, 50-383 Wrocław, Poland.
Marcin MączyńskiDepartment of Organic Chemistry, Faculty of Pharmacy, Wrocław Medical University, 211A Borowska Str, 50-556 Wrocław, Poland.ORCID 0000-0001-6110-344X
Wroclaw Medical University · PLPolish Academy of Sciences · PLUniversity of Wrocław · PL

Funding

Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu STM.D090.17.003
6 · The paper itself

Abstract

Thanks to the progress in oncology, pharmacological treatment of cancer is gaining in importance and in the near future anti-cancer chemotherapeutics are expected to be the main method of treatment for cancer diseases. What is more, the search for new anti-cancer compounds with the desired application properties is constantly underway. As a result of designed syntheses, we obtained some new

Indexed as

Cell Line, TumorCell ProliferationHumansHydrazinesHydrogen BondingInhibitory Concentration 50Hydrazines5-chloro-3-methylisothiazole-4-carboxylic acid hydrazide derivativesantiproliferative activityisothiazole

Identifiers

PMID31881700
PMCPMC6982951
OpenAlexW2997282189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.